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ABSTRACT 
Purpose Three- dimensional (3D) printing has received significant attention as a 
manufacturing process for pharmaceutical dosage forms.  In this study, we used Fusion 
Deposition Modelling (FDM) in order to print “candy – like” formulations by imitating 
Starmix sweets to prepare paediatric medicines with enhanced palatability.   
Methods Hot melt extrusion processing (HME) was coupled with FDM to prepare extruded 
filaments of indomethacin (IND), hypromellose acetate succinate (HPMCAS) and 
polyethylene glycol (PEG) formulations and subsequently feed them in the 3D printer.  The 
shapes of the Starmix objects were printed in the form of a heart, ring, bottle, ring, bear and 
lion. Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Fourier 
Transform Infra-red Spectroscopy (FT-IR) and confocal Raman analysis were used to assess 
the drug – excipient interactions and the content uniformity.  
Results Physicochemical analysis showed the presence of molecularly dispersed IND in the 
printed tablets. In vivo taste masking evaluation demonstrated excellent masking of the drug 
bitterness. The printed forms were evaluated for drug dissolution and showed immediate IND 
release independently of the printed shape, within 60min.  
Conclusions 3D printing was used successfully to process drug loaded filaments for the 
development of paediatric printed tablets in the form of Starmix designs.  
 
Keywords: 3D printing, paediatric medicines, fusion deposition modelling, hot melt 
extrusion, taste masking 
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INTRODUCTION 
The development of high quality, effective and safe paediatric medicines has been 
proven a challenging process for the pharmaceutical industry. Due to the substantial 
differences in the drug development process for paediatric patients and adult patients, new 
regulations were introduced by the European Medicines Agency (EMEA) in 2007, which 
governed the drug production strategies for paediatric medications.  According to Strickley et 
al., (2007) development difficulties are related to dose modification, ease of 
administration/swallowing, taste masking, physical stability, packaging and 
providing/designing the measuring device [1].  
The oral route of administration is often utilized as the route of choice for the delivery 
of medical products to paediatric patients, in both solid and liquid forms including; syrups, 
suspensions and emulsions; powders, granules, effervescent tablets, orodispersible tablets, 
chewable tablets and gums; mini tablets, innovative granules; and both conventional 
immediate release and modified release tablets and capsules [2]. A great disadvantage of 
liquid medications is the higher chance of error when measuring dosage for self-
administration. A number of studies have demonstrated that patients who self administer 
liquid medications have an estimated error rate of 50% to 60%, due to their inability to 
measure the correct dose  [3-5].  This problem can be avoided by manufacturing solid oral 
dosage forms which offer a number  advantages over the liquid forms, these include; having a 
lower cost of development, easy administration, greater stability, dose accuracy, have the 
capacity to develop modified release formulations, can be produced with greater uniformity 
and have greater taste masking capabilities [6]. Although oral administration is the most 
common route for paediatric populations, the development of palatable formulations is 
complicated. The developed medicines should be easily swallowed, taste masked while 
maintaining safety, efficacy, accessibility and affordability. Nevertheless, there is an 
increased demand for the development of novel technologies for paediatric patients that 
mainly focus on the formulation design and/or administration/dosing devices [7].  
Such a novel technology is 3D printing, which encompasses a wide range of additive 
manufacture processes, where products are designed using Computer Aided Design (CAD) 
software [8-11]. The product is then processed by a slicing software that divides the object 
into thin cross sections. These are then printed out one on top of the other, forming compact 
layers which form the 3D structure. The primary objective of the various 3D printing 
technologies is to develop and produce  models and prototypes of the designed product in a 
rapid and inexpensive manner [12]. The epitome of 3D printing applications for medicinal 
products is the recently approved 3D printed drug product called Spritam (levetiracetam) 
manufactured by using the Zipdose Technology based on a powder bed—liquid 3D printing 
technology. 
An increasing number of researchers are employing 3D printing technologies to 
develop oral dosage forms, with modified drug release profiles to allow either sustained or 
immediate drug release [13-15]. Recently, 3D printing was utilized to create a multi-active 
solid dosage form, containing 5 different API compartmentalised within the same capsule, 
which are autonomously controlled with two separate release profiles, called Polypill  [16]. 
An interesting approach was presented by Goyannes et al. where an anti-acne drug (salicylic 
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acid) loaded structure in the shape of a nose was prepared by comparing Fused Deposition 
Modelling (FDM) and stereolithography [17].  
However, FDM has proven to be one of the more versatile 3D printing methods due to 
the range of potential printing materials, which can be utilized on the system. However, 
further development of FDM extruders have allowed for the printing of almost any 
thermoplastic material such as polycarbonate and polyurethane [18]. Recently, the utilisation 
of FDM was extended to pharmaceutical materials where filaments of drugs and polymers are 
prepared and extruded through an FDM 3D printer. Specifically, FDM has been utilised to 
prepare formulations of differing shapes and infill ratio’s in order to tune the drug release 
profile [19, 20]. As expected tablets weights increased with an increasing infill percentage 
and same size, demonstrating high reproducibility in physical dimensions, along with high 
mechanical strength which is resistant to damage upon handling. Moreover,   extended 
release tablet of prednisolone were fabricated by using loaded poly(vinyl alcohol) (PVA) 
filaments [21]. The precision of dose control ranged between 88.7% and 107% while 
prednisolone existed in amorphous form within the PVA matrix and released from the 3D 
printed tablet over a 24hr period. Other work involves the development of Patient-Specific 
Immediate Release Tablets using theophylline loaded filaments as a mixture with PVP in the 
presence of plasticiser produced by means of hot melt extrusion. A 3D printing technique was 
applied to produce caplet-shaped tablets with excellent mechanical properties and an 
immediate in-vitro release pattern [22].  The aforementioned examples demonstrate that by 
simply modifying the printing patterns and structure, without altering the polymer-drug 
properties, it is possible to modify the drug dissolution rates.  
The aim of this work was to introduce the feasibility of 3D printing coupled with hot 
melt extrusion to prepare paediatric medicines that can be consumed easily by children from 
2 – 11 years old. The medicines were designed in such a way to imitate “sweet – like” 
chewable tablets. Chewable tablets are a valuable paediatric dosage form and have been used 
for various products such as antacids, antibiotics, anticonvulsants, analgesics, antiasthmatics 
and cold/allergy preparations. The proposed 3D printing approach improves compliance and 
adherence of children to the prescribed medication.  In addition the combined HME and 3D 
printing benefits such as taste masking and easy to swallow respectively, lead to dose 
accuracy and enhanced palatability.  For the purposes of the study “Starmix” (HARIBO 
PLC, UK) designs were printed using IND as model drug substance and HMPCAS as the 
polymeric excipient. Indomethacin is a nonsteroidal anti-inflammatory drug commonly used 
as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation 
and HPMCAS is a thermoplastic polymer which has been used primarily as an enteric coating 
material and dissolves at pH 5.5 – 6.8.  
 
MATERIALS AND METHODS 
Materials 
Indomethacin (IND) and polyethylene glycol (PEG) were purchased from Tokyo 
Chemicals (Belgium) and Sigma – Aldrich (U.K.) respectively. Hypromellose acetate 
succinate (HPMCAS, AQOAT AS-MF) was kindly donated by Shin – Etsu (Japan).  
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Extrusion of IND – HPMCAS filament 
A physical blend composed of indomethacin, HPMCAS and PEG 6000 at 20/60/20 
wt/wt ratio were accurately weighed and homogeneously blended in a Turbula shaker-mixer 
at 100rpm for 10 minutes. The blended physical mixer was loaded into a DD Flexwall 18 
feeder (Brabender Technology, Germany), and fed into a twin-screw extruder (Eurolab 16, 
Thermo Fisher, Germany) at a rate of 10g per minute. A circular shaped die was employed to 
yield polymer strand extrudates. The 9 heating zones across the barrel were set at the follow-
ing temperature profile; 40°C, 55°C, 75°C, 100°C, 140°C, 140°C, 140°C, 140°C, 120°C with 
the die temperature set at 80°C. The barrel was slightly cooled towards the end to allow the 
mixture to re-solidify, ensuring the end-product was extruded as a strand, which is uniform in 
diameter. A screw speed of 50 rpm was utilised.  
3D printing process of paediatric formulations   
The Starmix structures were printed by using a standard FDM printer HD2xR 
Airwolf (U.S.A). The structures were designed with SolidWorks (Dassault Systems, USA) 
and exported as .stl files which were subsequently imported into Cura software to generate 
the Gcode for the printing. The print temperature was 165oC and the print speed was set at 
25mm/sec. The infill percentage was 7% and the layer height 150μm. The size of the 
perimeter shell was 0.5mm and the top and bottom shell 0.4mm. No supports or rafts were 
utilised in the printed model. 
Scanning Electron Microscopy (SEM) 
The morphology of the extruded polymer strands and the 3D printed structure was 
observed via scanning electron microscopy (Hitachi SU8030, Japan). Both Samples were 
placed on an aluminium stub and coated with a thin layer of Mikrostik nonconductive 
adhesive (Agar scientific, UK). The samples were then plated with chromium under an 
atmosphere of argon. SEM images were taken using an electron beam accelerating voltage of 
2 kV. Images were captured between x30 and 2.00k magnifications.  
X-Ray Powder Diffraction (XRPD) 
X-ray powder diffraction was used to determine the solid state of the bulk materials, 
the extruded polymer strand and the polymer strand after 3D Printing. This was done using a 
D8 advanced x-ray Diffractometer (Bruker, Germany) in reflection mode. A Cu anode X-ray 
tube was powered at 40kV and 40mA. A primary Göbel mirror was used for the parallel 
beam and the removal of CuKβ.  A primary 4o Soller slit, a secondary 2.5o Soller slit and a 
0.6mm exit slit was selected for this experiment. Each sample was scanned from 2 to 60° 2θ 
with a step size of 0.02° 2θ degrees/step and a counting time of 0.2 sec/step. As the polymer 
samples were difficult to crush to a small enough size to run for XRPD, they were first 
doused in liquid nitrogen then ground in a mortar and pedestal, before being placed in a low 
background holder and inserted into the device. DIFFRAC.EVA software was used for the 
phase analysis.  
Differential Scanning Calorimetry (DSC) 
The temperature profiles of the bulk ingredients and extruded strands were analysed 
using a differential scanning calorimeter (Mettler-Toledo 823e, Greifensee, Switzerland). The 
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samples were accurately weighed between 3mg-5mg and placed into an aluminium pan and 
crimped. Each sample was heated from 0°C to 300°C at 10°C/min heating rate except for 
PEG 6000 which was heated to 150°C. Nitrogen gas was used as a purge, at a flow rate was 
set at 50ml/min. STARe excellence software was used to analyse the data. 
Fourier Transform Infra-red Spectroscopy (FT-IR) 
FTIR analysis was performed on the drug, carrier, drug/carrier physical mixtures, and 
complex using PerkinElmer PE1600 (Massachusetts 02451, USA) Fourier transform infrared 
spectra according to the KBr disc method from 400 to 3600 wavelength/cm−1 range. For FT-
IR analysis, amorphous IND was prepared by using solvent evaporation method where IND 
dissolved in methanol following by rapid evaporation of the solvent. 
Confocal Raman analysis 
Room temperature Raman spectra of the “pure” formulation components were 
obtained using a Jobin/Yvon LabRam 320 instrument equipped with an Olympus microscope 
(Horiba, Japan). The spectrometer is equipped with an 1800 grooves/mm holographic grating, 
a holographic notch filter, a Peltier-cooled CCD (MPP1 chip) for detection, and an Olympus 
BX40 microscope. An Ar+ ion laser (λ = 633 nm) was used. Raman spectra of solid-state 
samples were collected at room temperature on a microscope slide using a microscope 
objective of 50× magnification to focus the laser beam. A backscattering (180° between 
excitation and collection) geometry was used in all experiments. Each spectral scan was 
collected for 5 s using 4 accumulations. The Raman instrument was calibrated using the v1 
line of silicon at 520.7 cm−1.  
Raman mapping was performed using a Jobin/Yvon LabRam 320 instrument 
equipped with an Olympus microscope (Horiba, Japan) by means of Ar+ ion laser (λ = 532.8 
nm) and 1800 l/nm grating on 3 different particles for each formulation. The experimental 
conditions were: 100 nm slit width, a 50× Microsoft objective and 0.4 s acquisition time. 
Each spectrum was the mean of the two. The sample profiling was performed at step 
increments of 3 μm in the X–Y direction covering the biggest possible surface of the part. 
Principal component analysis (PCA) was applied to identify the number of components and 
plot the chemical maps. Prior to analysis, the spectra baseline was checked by using the 
automatic weighted least square and normalised to the unit area to avoid deviation among the 
Raman spectra. 
 
Taste masking of 3D designs 
In vivo taste masking evaluation was performed on 10 healthy human volunteers from 
whom informed consent was first obtained (approved by the Ethics Committee of the 
University of Greenwich). The study is also in accordance to the Code of Ethics of the World 
Medical Association (Declaration of Helsinki).  The healthy volunteers of either sex (age 18–
25) were selected, trained and the one Stramix design was held in the mouth for another 120 
s, and then spat out. The mouth was rinsed with water without swallowing the tablet. The 
equivalent of 50mg of bulk IND was held in the mouth for 30 s and then spat out. Bitterness 
was recorded immediately to the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4, and 5 
indicate no, threshold, slight, moderate, and strong bitterness. 
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 In vitro dissolution studies 
Dissolution studies were conducted by using a USP II paddle apparatus (Varian 705, 
US). The amount of extruded powders was equivalent to 25 mg of IND, placed into 900 mL 
of phosphate buffer solution (pH 6.8), in each dissolution vessel (n = 3). The temperature of 
the dissolution media was maintained at 37 °C with a paddle rotation of 100 rpm. Samples, 
about 2−3 mL, were withdrawn at 10, 20, 30, 60, 90 and 120 min intervals and filtered with a 
200 μm filter prior to HPLC analysis. 
HPLC analysis 
The content of IND in dissolution samples was determined by HPLC. The samples 
were analysed on an HPLC system (Agilent Technologies, 1200 series) equipped with a 
quaternary pump using a Hichrom S50DS2-4889 (5 μm × 150 mm × 4 mm) column. The 
column temperature time was set at 25 °C while the retention time was 4 min. The mobile 
phase consisted of 70:30:0.2 (v/v/v) methanol/water/acetic acid and the injected sample 
volumes were 20 μL, the flow rate was 1.5 mL/min, and the detector was set at a wavelength 
of 260 nm. The calibration curve for IND was plotted over a concentration range of 10−50 
μg/mL. 
 
RESULTS AND DISCUSSION 
Hot melt extrusion (HME) and 3D printing coupling 
HME is a well-known processing pharmaceutical technology that has been 
successfully used over the past twenty years to increase the solubility of water insoluble 
drugs and mask the taste of bitter APIs for paediatric applications by producing solid 
dispersions [23]. In this study, HME was employed as the core technique to produce printing 
filaments and subsequently coupled with a 3D printer. HME nowadays is the predominant 
technique to create filaments of pharmaceutical compounds which can be subsequently 
inserted into the 3D printer. The active pharmaceutical ingredient (API) is introduced either 
by soaking [24] or by extrusion [25-27]. IND was selected as a model API as it has been 
previously reported to produce extruded solid dispersions with increased solubility while 
HPMCAS is a suitable thermoplastic career for manufacturing of drug loaded strands. The 
main aim of the study was to manufacture taste masked IND/HPMCAS solid dispersions with 
increase drug solubility in the form of strands/filaments that could be fed to the 3D printer 
and produce paediatric chewable tablets. According to Lopez et al., the capability of children 
to swallow solid dosage forms is a major issue and thus chewable tablets are an excellent 
paediatric dosage form [3].  They can be administrated to children of 2 years old and older 
where swallowing or disintegration is assisted by the patient.  
The design of the chewable tablets was inspired by the Starmix flavour gummy 
sweets (HARIBO plc.) to appear as “candy – like” formulations. By imitating these popular 
confectionaries the 3D printed chewable tablets aim to improve patient compliance and 
palatability.  
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Process optimisation 
Premixed drug, polymer and plasticiser blends were fed into the extruder in order to 
produce drug-loaded filaments suitable for 3D printing. One of the most critical features is 
the filament quality, which should be flexible enough to prevent any breakage printing.  For 
that purpose, PEG was added as a plasticiser to facilitate better extrusion processing and 
enhance the strand flexibility.  Various polymer/plasticiser ratios were tested (data not 
shown) to concluded that 20% PEG was giving the best filament quality. The diameter of the 
filament was adjusted between 2.7 and 2.9mm, to meet the 3D printer specifications. Due to 
the HPMCAS/PEG swelling at the end of the extrusion process a die of 1mm was selected to 
process the formulations.  
 
 
Fig. 1: Photographic image of the 3D printed medicines loaded with IND as model substance 
 
As shown in Fig. 1 various Starmix IND loaded structures were printed at a wide 
range of designs. By using SolidWorks the process was programmed with 5% infill ratio 
25mm s-1 printing speed and 160μm layer thickness in order to print doses of 25mg IND per 
structure. The printing time for each Starmix tablet was 5min. 
The 3D printing optimisation process was a prerequisite to achieving excellent bonding 
between the layers and thus fine 3D printed structures. All Starmix structures were printed 
at temperatures of 165oC much higher than those used to extrude the exact same 
formulations. This can be explained by the effect of the extrusion process (e.g. screw 
configuration, temperature profile), which results in higher torque and consequently reduces 
significantly the melt viscosity of the extruded formulations.  In addition, due to the small 
size of the 3D printing nozzle further temperature increase is required to reduce the melt 
viscosity of the filament and achieve the optimum printing conditions. Due to the complexity 
of the designs the weight of the individual printed forms was adjusted to deliver 50mg of  
IND according to the initial drug/polymer ratio. The 3D printing of Starmix designs was 
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highly accurate, reproducible and produced smooth structures without any defects. 
Nevertheless, a weight and content uniformity variation of 5-10% was observed due the some 
inconsistencies of the filament thickness.  The variations observed on tablet size were 
negligible.  
Scanning Electron Microscopy  
The topography of the filament and the 3D printed structure was investigated by 
means of SEM. As illustrated in Fig 2a, the hot melt extruded filament presented a 
homogeneous and very smooth surface without any defects suggesting a perfect extrusion 
processing. No drug particles could be observed on the filament surface indicating very good 
IND blending and content uniformity (see further analysis). The manufacturing of high 
quality filaments is a prerequisite in order to facilitate robust 3D printing process with the 
required resolution of the printed designs.  Fig. 2c shows the layer by layer deposition of the 
printed layers which appear to be uniform with close packing. The thickness of the layers 
were estimated at 150 - 180 m. 
 
Fig. 2: SEM images of a) extruded filament, b) surface of the extruded filament and c) 
surface of 3D structure 
 
Thermal Analysis 
Thermogravimetric analysis (TGA) was used to examine the thermal stability of 
pharmaceutical ingredients under the hot melt extrusion and 3D printing processing 
temperatures. In Fig. 3, IND showed that a negligible mass loss (0.5%) up to 170oC followed 
by a fast mass loss at around 220oC due to its degradation. AQOAT exhibited a small mass 
loss (2.7%) from 30 - 170oC and a second at 250oC which corresponds to its degradation. 
PEG was extremely stable at high temperatures without any losses and only presented a fast 
mass loss at 320oC due to its degradation. Both filament and the 3D printed Starmix 
structures demonstrates identical mass loss pathways showing that all mixtures remain stable 
up to 250oC with 2.8% mass loss, which is higher than the degradation temperature of IND 
indicating interactions among the polymers and the drug substance. Above this temperature, 
both samples exhibited a fast mass loss due to degradation. Overall, the TGA profiles 
demonstrate that the HME filament is suitable for 3D printing temperature at 165oC.    
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Fig. 3: TGA graph of the bulk IND, HPMCAS, PEG, extruded filament and 3D printed 
structure 
 
 
Fig. 4: DSC thermograph of pure IND, PEG, HPMCAS, extruded filament and 3D printed 
strucutre 
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DSC was conducted to investigate the physicochemical properties of the bulk 
materials the extruded filament and the 3D structures. As shown in Fig 4, IND exhibits a 
strong endothermic peak at 160.99oC which is typical for the crystalline γ-form while PEG 
6000 exhibits a melting endotherm at 62oC. HPMCAS is an amorphous polymer with a glass 
transition at 131oC while it presents an exothermic peak at 175oC indicating crystallisation 
followed by a degradation endothermic peak at 191.8oC.  The extruded filament shows a 
melting endotherm at 52.16o corresponding to PEG 6000 melting point suppression while no 
IND melting endotherm can be observed suggesting that the drug is in amorphous or 
molecularly dispersed form. A thermal endotherm appears at 223.5oC which is probably 
related to the HPMCAS degradation.  Interestingly, in the thermogram of the 3D printed 
structures the PEG 6000 melting endotherm has disappeared suggesting that the polymer has 
turned to its amorphous state due to the second thermal processing (3D extrusion).  
 
X-Ray Diffraction  analysis 
X-ray analysis was performed in order to verify the physical state of IND in the 3D 
printed designs. The XRD diffractogram of bulk IND, HPMCAS, filament and 3D printed are 
illustrated in Fig. 5. The XRD of bulk IND presents strong intensity peaks at 11.6°, 16.4°, 
19.6°, 26.89°, and 29.3° 2θ values which correspond to γ-IND [28]. The HPMCAS 
diffractogram does not depict any intensity peaks due to the amorphous nature of the 
polymer, while PEG showed strong intensity peaks at 15o and 24o.  The XRD of the extruded 
filament revealed two small peaks at 15o and at 24o 2θ values, which are indicative of PEG 
suggesting that a part of the plasticiser is still in the crystalline state. This observation is also 
in good agreement with the DSC analysis where the PEG melting endotherm was identified. 
In contrast, the diffractograms of the 3D printed structure did not reveal any intensity peaks 
and the two PEG peaks have disappeared indicating that PEG has turned to completely 
amorphous state. This was attributed to the effect of the filament re-heating during the 
printing process, which occurs at higher temperature compared to the HME process.   
 
Fig. 5: XRD graphs of IND, HPMCAS, PEG, extruded  filament and 3D printed structure 
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FT-IR Spectroscopy 
FT-IR analysis of the extruded formulations and the 3D printed structures was used to 
examine possible interactions among the compounds. Specifically, the carbonyl groups (-CO) 
and  hydroxyl group (-OH) of IND can form hydrogen bonds with the -OH and COOH 
groups of AQOAT respectively. Such interactions of IND have previously reported with 
saccharin [29], polyvinyl pyrrolidone [30] and hydroxypropyl-β-cyclodextrin [31]. The DSC 
and XRD analysis showed the presence of IND in amorphous form within the extruded 
filaments and printed structured. Therefore, amorphous IND was prepared in order to identify 
the related peak shifting compared to the crystalline form. Fig. 6 demonstrates that crystalline 
of γ-form indomethacin contains benzoyl and acid carbonyl groups corresponding at 1717cm-
1 and 1690cm-1 respectively, whereas in amorphous form these peaks have moved towards 
lower wavenumbers at 1708cm-1 (presence cyclic dimers) and 1680cm-1 respectively. This 
observation is in good agreement with the published work by Taylor and Zografi [32]. In the 
3D printed structure and filament the acid carbonyl group has moved to 1685cm-1 whereas 
the benzoyl peak overlapped by the strong carbonyl peak of HPMCAS indicating H-bonding 
interactions. The amorphous state of IND in HPMC solid dispersions has also confirmed by 
other groups [33, 34], and it is attributed to the molecular mobility of IND within the polymer 
matrix. Another interesting observation is that the carbonyl peak of HPMCAS has shifted 
towards lower wavenumbers from 1745cm-1 to 1733cm-1 only for the 3D printed structure. 
This is due to the additional heat processing of the filament, suggesting stronger H-bonding 
interactions of the IND/HPMCAS blend.  
 
Fig. 6: FT-IR graphs of PEG, HPMCAS, Filament, 3D printed mixture Amorphous IND and 
powder IND in the region of 1550 – 1900cm-1  
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Raman Mapping 
Fig. 7 shows the Raman spectra of the bulk compounds, extruded filament and 3D 
printed structures in the range of 1580 cm-1 – 1700 cm-1 wavenumbers. Characteristic peaks 
of IND appear in the 1580 – 1625 cm-1 region, HPMCAS at 1740 cm-1 and PEG at 1200 – 
1300 cm-1.  Previous studies showed that the peak at 1702 cm-1 corresponds to benzoyl 
carbonyl vibration while the peaks associated with the symmetrical stretching vibrations of 
the cyclic dimer formed by the carboxyl groups are not active in the Raman spectra [32]. In 
amorphous IND the peak is shifted towards lower wavenumbers at 1684 cm-1.   
 
Fig. 7: Raman Spectra of bulk HPMCAS, PEG 6000, crystalline and amorphous IND 
In order to investigate the IND homogeneity within the printed structures, multivariate 
data analysis PCA was applied to reduce the number of variables and identify the number of 
loadings, which consist the hyperspectral Raman data. Based on the eigenvalues, the 
hyperspectral data can be described by two principal components (PCs). This is a typical 
observation in multivariate data analysis of Raman spectra, which leads arbitrarily to the 
assumption that there are only two components in the system, as the first PC corresponds to 
the features of the strongest spectral contributors. It can be clearly observed from Fig. 8b that 
the peaks of the first PC correspond to characteristic of amorphous IND and HPMCAS in the 
formulation, which overwhelms the PEG’s peaks. For instance, the characteristic pattern of 
IND peaks appears in the 1550 cm-1 - 1650 cm-1 region whereas several characteristic peaks 
of HPMCAS appear at 1366 cm-1, 1456 cm-1, and 1739 cm-1 wavenumber. The characteristic 
peaks of PEG appear in the 4th PC at 840 cm-1 – 885 cm-1 region and further at 1236 cm-1, 
1282 cm-1 and at 1486 cm-1 wavenumbers, whereas the intermediate PCs are attributed to the 
noise and are not represented. Furthermore, the peaks, of PC4 assigned to IND and HPMCAS 
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(Fig. 8b) at 1685 cm-1 and 1739 cm-1 respectively, confirm the homogeneity of the analysed 
samples. The Raman mapping analysis in Fig 2b showed that in the concentration maps (200 
x200m) corresp to PC1 and PC4, IND is uniformly distributed in the bulk across the 
scanned areas while the coloured areas overlap indicating the existence of a molecular 
dispersion.  
 
 
Fig. 8: a) Variation of Eigenvalues with the principal components, b) Comparison of 
HPMCAS and amorphous IND with the PC1 and PC4 where $ correspond to PEG 6000, * to 
HMPCAS and & to IND, c) Concentration map of PC1, d) Concentration map of PC4  
 
Taste masking evaluation 
Taste masking efficiency of the 3D Starmix designs was of the utmost importance 
for the purpose of paediatric applications [35, 36]. We anticipated that the selection of the 
excipients and the HME processing will result in efficient masking of IND bitterness and 
increase the palatability of the printed designs. As shown in Fig. 9 the panellist evaluation 
revealed moderate bitterness for IND while slight and threshold for PEG and HPMCAS 
respectively. All 3D printed designs showed excellent taste masking with no bitterness at all 
and no aftertaste was reported.  The masking effect is attributed to the drug – polymer 
interactions through H- bonding facilitated by HME processing [37]. The effective taste 
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masking of the Starmix designs suggests that 3D printed dosage forms can be successfully 
used in paediatric applications providing enhanced palatability.  
 
Fig. 9: Taste masking evaluation graph of bulk IND, HPMCAS, PEG and Starmix  designs 
 
 
Figure 10: Dissolution rate of IND in three different 3D printed structure 
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 Dissolution studies 
As HPMCAS dissolves at pH>6 we anticipated IND release in the mouth. However, 
children are expected to chew the tablets for a few minutes (up to 2min) and subsequently 
swallow them. For this reason, IND release was initially investigated similarly to Rachid et al 
by using small volumes (2ml) of simulated saliva (data not shown) [38].  The release of IND 
was found to vary from 8.0 – 12x10-3% which is negligible to cause any bitterness.  These 
findings support the taste evaluation where the 3D printed tablets were found to mask IND 
bitternes.  
In addition, the IND release profiles of four printed Starmix designs were conducted 
in phosphate buffer (pH 7.4). The release profiles are illustrated in Fig 10 where it can be 
observed that for each printed form more than 80% of the drug was released within the first 
60 min while the Starmix designs were completely dissolved.  
The rapid IND release was facilitated by the fact that HPMCAS is highly soluble in 
pH> 6.0 and IND is molecularly dispersed within the printed forms. Interestingly, the release 
profiles of all Stramix designs are very similar and no significant difference was observed 
(p<0.05). It is also important to mention that the optimized printing process achieved release 
patterns independent of the printed designs. This is a crucial feature for the development of 
oral dosage forms with multiple designs or patterns.  However, the alignment of drug release 
from 3D printed dosage forms was also observed by Goyanes et al. where tablets of different 
shapes and similar weights provided similar drug release profiles [20].  
 
CONCLUSION 
Starmix designs were manufactured by using FDM 3D printing coupled with HME 
processing for the development of palatable paediatric dosage forms.  FDM process was 
proved efficient in printing detailed Starmix designs with high reproducibility, accuracy 
and content uniformity. Physicochemical characterisation studies showed that IND was 
molecularly dispersed in the HPMCAS matrix. The panellist taste evaluation showed 
excellent taste masking efficiency and hence enhanced palatability.  The drug release profiles 
showed rapid IND release independent of the shape of printed design. Overall, we 
demonstrated that 3D printing can be used as an alternative manufacturing route for 
paediatric medicines. 
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